FrancophonIA/ELRC3.0 huggingface dataset:
English: − to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, and
Estonian: − L. interrogans'i serogrupi Canicola serotüübist Canicola ja L. interrogans'i serogrupi Icterohaemorrhagiae serotüübist Icterohaemorrhagiae põhjustatud kliiniliste nähtude ja uriiniga eritamise ärahoidmiseks ning infektsiooni vähendamiseks, ja
English: Duration of immunity: At least one year following the primary vaccination course for all components of Versican Plus Pi/L4.
Estonian: Kõigi Versican Plus Pi/L4 koostisosade vastu vähemalt üks aasta pärast esmase vaktsineerimiskuuri lõpetamist.
English: PACKAGE LEAFLET: Versican Plus Pi/L4 lyophilisate and suspension for suspension for injection for dogs
Estonian: PAKENDI INFOLEHT Versican Plus Pi/L4, süstesuspensiooni lüofilisaat ja suspensioon koertele
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus Pi/L4 lyophilisate and suspension for suspension for injection for dogs
Estonian: VETERINAARRAVIMI NIMETUS Versican Plus Pi/L4, süstesuspensiooni lüofilisaat ja suspensioon koertele
English: L. interrogans serovar Icterohaemorrhagiae
Estonian: L. interrogans, serotüüp Icterohaemorrhagiae ALR tiiter ≥ 1 : 51 L. interrogans, serotüüp Canicola
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus Pi/L4 suspension for dogs
Estonian: VETERINAARRAVIMI NIMETUS Versican Plus Pi/L4 süstesuspensiooni lüofilisaat ja suspensioon koertele
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus Pi/L4 lyophilisate for dogs
Estonian: Versican Plus Pi/L4 lüofilisaat koertele
English: DATE OF REVISION OF THE TEXT
Estonian: Kordusvaktsineerimise skeem
English: Dose and route of administration:
Estonian: Annustamine ja manustamistee
English: Potassium chloride Potassium dihydrogen phosphate Disodium phosphate dodecahydrate Water for injections
Estonian: Suspensioon: naatriumkloriid, kaaliumkloriid, kaaliumdivesinikfosfaat, dinaatriumfosfaatdodekahüdraat, süstevesi.
English: International non-proprietary name (INN): tilmicosin
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): tilmikosiin
English: The Committee appointed Mr G. Johan Schefferlie as rapporteur and Dr Michael Holzhauser-Alberti as co-rapporteur.
Estonian: Komitee määras hindajaks G. Johan Schefferlie ja kaashindajaks dr Michael Holzhauser-Alberti.
English: Written explanations were provided by the marketing authorisation holders on 18 September 2012, 11 February 2013 and 26 May 2013.
Estonian: Müügiloa hoidjad esitasid kirjalikud selgitused 18. septembril 2012, 11. veebruaril 2013 ja 26. Mail 2013.
English: Oral explanations were given on 11 June 2013.
Estonian: Suulised selgitused anti 11. juunil 2013.
English: The final opinion was converted into a Decision by the European Commission on 18 October 2013.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 18. oktoobril 2013.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended Summary of Product Characteristics, labelling and package leaflet in Annex III.
Estonian: Asjaomased raviminimetused on esitatud I lisas, teaduslikud järeldused II lisas ning ravimi omaduste muudetud kokkuvõte, märgistus ja pakendi infoleht III lisas.
English: Due to divergent national decisions taken by Member States concerning the authorisations of Micotil 300 Injectie and its associated names, on 24 April 2012 the Netherlands referred the issue to the CVMP under Article 34(1) of Directive 2001/82/EC, in order to resolve discrepancies in the product information across the European Union.
Estonian: Et Micotil 300 Injectie ja sarnaste nimetuste müügilubade kohta on liikmesriikides vastu võetud erinevaid otsuseid, tegid Madalmaad 24. aprillil 2012 veterinaarravimite komiteele direktiivi 2001/82/EÜ artikli 34 lõike 1 kohase esildise, et kaotada erisused riikide ravimi omaduste kokkuvõtetes kogu Euroopa Liidus.
English: Tilmicosin is a macrolide antibiotic synthesized from tylosin which has an antibacterial spectrum similar to tylosin with enhanced activity against Pasteurella multocida and Mannheimia haemolytica.
Estonian: Tilmikosiin on tülosiinist sünteesitud makroliidantibiootikum, millel on tülosiiniga sarnane antibakteriaalne spekter ja suurenenud toime bakterite Pasteurella multocida ja Mannheimia haemolytica vastu.
English: Micotil 300 Injectie and its associated names are veterinary medicinal products authorised for use in the target species cattle, sheep and rabbits for treatment of various infections caused by microorganisms susceptible to tilmicosin.
Estonian: Micotil 300 Injectie ja sarnased nimetused on veterinaarravimid, millel on müügiluba kasutamiseks sihtliikidel veistel, lammastel ja küülikutel, et ravida mitmesuguseid tilmikosiini suhtes tundlikest mikroorganismidest põhjustatud infektsioone.
English: Based on the currently available data, the CVMP considered that the benefit-risk profile of Micotil 300 Injectie and its associated names remains positive, subject to variation of the marketing authorisations in accordance with the recommended product information.
Estonian: Seni kättesaadavate andmete põhjal leidis veterinaarravimite komitee, et Micotil 300 Injectie ja sarnaste nimetuste kasulikkuse ja riski tasakaal on endiselt positiivne, kui müügilubadesse tehakse parandused vastavalt soovitatud muudatustele ravimiteabes.
English: Opinion following an Article 341 referral for Micotil 300 Injectie and its associated names
Estonian: Arvamus pärast artikli 341 kohast esildist Micotil 300 Injectie ja sarnased nimetused
English: 18 October 2013
Estonian: 18. oktoober 2013 EMA/539469/2013
English: Opinion following an Article 340F referral for Micotil 300 Injectie and its associated names
Estonian: Arvamus pärast artikli 340F kohast esildist Micotil 300 Injectie ja sarnased nimetused EMA/696370/2013
English: Posaconazole SP 40 mg/ml Oral suspension Oral use
Estonian: Posaconazole SP 40 mg/ml Peroraalne suspensioon Peroraalne
English: Content (concentration) Package size
Estonian: Pakendi suurus
English: Immediate Packaging Pack size blister (PVC/PE/PCTFE/alu) Initiation pack: 63 (7 x 3 and 7 x 6) capsules blister (PVC/PE/PCTFE/alu) 252 x 1 capsules (unit dose)
Estonian: Sisepakendi iseloomustus blister (PVC/PE/PCTFE/alu) blister (PVC/PE/PCTFE/alu) HDPE-pudel HDPE-pudel
English: 270 capsules blister (PVC/Aclar (PCTFE)) Initiation pack: 63 (1 x 21 and 2 x 21) tablets
Estonian: Ravi alustamise pakend: 63 (1 x 21 ja 2 x 21) tabletti
English: Route of Administration
Estonian: Sisepakendi iseloomustus
English: Strength Pharmaceutical Form
Estonian: Õhukese polümeerikattega tablet
English: What measures are being taken to ensure the safe and effective use of Instanyl?
Estonian: Mis meetmed võetakse, et tagada Instanyli ohutu ja efektiivne kasutamine?
English: Further information on Instanyl can be found on the Agency's website: ema.europa.eu/medicines/Human/EPAR/Instanyl.
Estonian: Lisateave Instanyli kohta on ameti veebilehel: ema.europa.eu/medicines/Human/EPAR/Instanyl.
English: Instanyl received a marketing authorisation valid throughout the EU on 20 July 2009.
Estonian: Instanyli müügiluba, mis kehtib kogu Euroopa Liidus, anti 20. juulil 2009.
English: This overview was last updated in 03-2019
Estonian: Kokkuvõtte viimane uuendus: 03.2019.
English: The European Medicines Agency decided that Instanyl's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Instanyli kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The doctor should keep in mind the potential for Instanyl to be abused.
Estonian: Arst peab arvestama võimalust, et Instanyli võidakse kuritarvitada.
English: What is Instanyl what is it used for?
Estonian: Mis on Instanyl ja milleks seda kasutatakse?
English: Side effects are similar to those of other medicines containing fentanyl, and measures have been put in place to minimise the risk of misuse and overdose.
Estonian: Kõrvalnähud on sarnased muude fentanüüli sisaldavate ravimite kõrvalnähtudega ning on võetud meetmeid, et minimeerida kuritarvitamise ja üleannustamise riski.
English: As for all medicines, data on the use of Instanyl are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Instanyli kasutamise kohta pidevat järelevalvet.
English: What are the risks associated with Instanyl?
Estonian: Mis riskid Instanyliga kaasnevad?
English: The medicine can only be obtained by ‘special' prescription.
Estonian: Seda ravimit saab üksnes eriretsepti alusel.
English: Other information about Instanyl
Estonian: Muu teave Instanyli kohta
English: The company that markets Instanyl will also provide educational materials to be supplied to patients, doctors and pharmacists, explaining the correct and safe use of the medicine.
Estonian: Instanyli turustaja annab patsientidele, arstidele ja apteekritele jagatavad koolitusmaterjalid, milles selgitatakse ravimi õiget ja ohutut kasutamist.
English: It is available in singledose containers and in multidose containers.
Estonian: Seda turustatakse ühe- ja mitmeannuselistes mahutites.
English: If there has been insufficient pain relief, the same dose can be given again at the earliest after 10 minutes.
Estonian: Kui valuleevendus on ebapiisav, tohib sama annust korrata kõige varem 10 minuti pärast.
English: Side effects reported with Instanyl are carefully evaluated and any necessary action taken to protect patients.
Estonian: Instanyli kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: In a third study, which involved 139 patients and compared Instanyl with ‘transmucosal' fentanyl (absorbed through the lining of the mouth), patients who received Instanyl had faster pain relief than patients who received transmucosal fentanyl .
Estonian: Kolmandas uuringus, milles osales 139 patsienti ja milles võrreldi Instanyli transmukoosse fentanüüliga (imendub suu limaskesta kaudu), leevendus Instanyli kasutanud patsientidel valu kiiremini kui transmukoosset fentanüüli kasutanutel.
English: For more information about using Instanyl, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Instanyli kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Instanyl have also been included in the summary of product characteristics and the package leaflet.
Estonian: Instanyli ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: A patient's breakthrough pain was considered to have responded to treatment if there was a reduction of at least 2 points.
Estonian: Patsiendi läbimurdevalu peeti ravile reageerivaks, kui valu intensiivsus vähenes vähemalt 2 punkti võrra.
English: Because fentanyl has been in use for many years, the company presented data from the scientific literature, as well as from studies that it had carried out, which showed that Instanyl was more effective than placebo (a dummy treatment) at treating breakthrough pain in cancer patients.
Estonian: Et fentanüüli on kasutatud palju aastaid, esitas ettevõte teaduskirjanduse andmed ning oma uuringute andmed, mis tõendasid, et Instanyl oli efektiivsem kui platseebo (näiv ravim) läbimurdevalu ravis vähipatsientidel.
English: How is Instanyl used?
Estonian: Kuidas Instanyli kasutatakse?
English: Before starting treatment with Instanyl, the patient's long-term pain should be well controlled by opioid pain killers and they should have no more than 4 episodes of breakthrough pain a day.
Estonian: Enne Instanyl-ravi alustamist peab patsiendi krooniline valu olema hästi ohjatud opioid-valuvaigistitega ja tal ei tohi olla üle 4 läbimurdevaluepisoodi päevas.
English: The most common side effects with Instanyl (which may affect up to 1 in 10 people) are somnolence (sleepiness), dizziness, headache, vertigo (a spinning sensation), flushing (reddening of the skin), hot flushes, throat irritation, nausea (feeling sick), vomiting and hyperhidrosis (excessive sweating).
Estonian: Kõige sagedamad Instanyli kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on somnolentsus (unisus), peapööritus, peavalu, vertiigo, õhetus (nahapunetus), kuumahood, kurguärritus, iiveldus, oksendamine ja hüperhidroos (liighigistamine).
English: Instanyl must not be used in patients who are not already taking opioids to maintain pain control, who have severe respiratory depression (inhibition of breathing) or who have severe obstructive lung conditions (diseases that severely impede breathing).
Estonian: Instanyli ei tohi kasutada patsiendid, kes ei saa valuraviks opioidravi, kellel on raske hingamisdepressioon (hingamise pärsitus) või kellel on rasked obstruktiivsed kopsuhaigused (hingamist oluliselt takistavad haigused).
English: When the patient sprays Instanyl into the nose, a dose of fentanyl is absorbed into the blood stream through the blood vessels in the nose.
Estonian: Kui patsient pihustab Instanyli ninna, imendub fentanüüli annus ninas olevate veresoonte kaudu kiiresti vereringesse.
English: In one main study, 178 adult cancer patients with breakthrough pain took one spray of either Instanyl (50, 100 or 200 microgram) or placebo when they experienced breakthrough pain.
Estonian: Ühes põhiuuringus osalenud 178 täiskasvanud läbimurdevaluga vähipatsienti manustasid läbimurdevalu tekkimisel kas ühe pihuse Instanyli (50, 100 või 200 µg) või platseebot.
English: The number of patients who responded to treatment was also higher in the Instanyl group than in the placebo group.
Estonian: Ravivastusega patsientide arv oli samuti suurem Instanyli kui platseebo rühmas.
English: In another main study, 128 patients were given increasing doses of Instanyl until the adequate dose for pain relief was reached.
Estonian: Teises põhiuuringus manustati 128 patsiendile Instanyli suurenevas annuses kuni valu leevendamiseks piisava annuseni.
English: What benefits of Instanyl have been showed in studies?
Estonian: Milles seisneb uuringute põhjal Instanyli kasulikkus?
English: Instanyl is available as a nasal spray (50, 100 and 200 micrograms per dose).
Estonian: Instanyli turustatakse ninaspreina (50, 100 ja 200 mikrogrammi (µg) annuse kohta).
English: The patient should be given Instanyl for a maximum of 4 episodes of breakthrough pain a day.
Estonian: Patsiendile tohib Instanyli manustada maksimaalselt 4 läbimurdevaluepisoodi kohta ööpäevas.
English: Instanyl is a medicine used to treat breakthrough pain in adults with cancer.
Estonian: Instanyl on ravim, mida kasutatakse läbimurdevalu raviks täiskasvanud patsientidel, kellel on vähk.
English: Each patient then used the identified dose of Instanyl or placebo to treat breakthrough pain.
Estonian: Seejärel kasutas iga patsient läbimurdevalu raviks Instanyli määratud annust või platseebot.
English: The active substance in Instanyl, fentanyl, is an opioid.
Estonian: Instanyli toimeaine fentanüül on opioid.
English: The change in pain intensity after 10 minutes was between 2.0 and 2.7 points after receiving doses of Instanyl compared with 1.3 after receiving placebo.
Estonian: Valu intensiivsuse muutus 10 minuti pärast oli vahemikus 2,0-2,7 punkti pärast Instanyli annuste manustamist ja 1,3 pärast platseebot.
English: The highest dose was 200 microgram given as one spray in one nostril and the patients were allowed to take a second spray after 10 minutes if there had been insufficient pain relief.
Estonian: Suurim annus ühe pihusena ühte ninasõõrmesse oli 200 µg ja patsiendid tohtisid 10 minuti pärast pihustada ravimit teist korda, kui valu leevendus ei olnud piisav.
English: How does Instanyl work?
Estonian: Kuidas Instanyl toimib?
English: Instanyl contains the active substance fentanyl.
Estonian: Instanyl sisaldab toimeainena fentanüüli.
English: The number of breakthrough pain episodes that responded to treatment was also higher among patients who received Instanyl than those who received placebo.
Estonian: Läbimurdevalu ravivastusega episoodide arv oli samuti suurem Instanyli kui platseebot kasutanud patsientidel.
English: The reduction in pain intensity after 10 minutes was between 1.8 and 2.7 points on an 11-point pain scale for patients who took Instanyl, compared with 1.4 for patients who took placebo.
Estonian: 11-punktisel valuskaalal vähenes valu intensiivsus pärast 10 minutit 1,8-2,7 punkti Instanyli kasutanud patsientidel ja 1,4 punkti platseebot kasutanutel.
English: Patients taking Instanyl were allowed to take a second spray 10 minutes after the first dose if there had been insufficient pain relief.
Estonian: Patsiendid, kes kasutasid Instanyli, tohtisid 10 minuti pärast esimest annust pihustada teise annuse, kui valu ei leevendunud piisavalt.
English: An overview of Instanyl and why it is authorised in the EU
Estonian: Ülevaade ravimist Instanyl ja ELis müügiloa väljastamise põhjendus
English: Once in the bloodstream, fentanyl acts on receptors in the brain and spinal cord to relieve pain.
Estonian: Vereringes olev fentanüül toimib pea- ja seljaaju retseptoritele, vaigistades valu.
English: Treatment with Instanyl should be started by and remain under the supervision of a doctor who has experience in the management of opioid treatment in cancer patients.
Estonian: Ravi Instanyliga peab alustama ja jälgima vähipatsientide opioidravis kogenud arst.
English: Instanyl is used in patients who are already using opioids (a group of painkillers that includes morphine and fentanyl) to control long-term cancer pain.
Estonian: Instanyli kasutatakse vähivalu pikaajaliseks ohjamiseks patsientidel, kes juba kasutavad opioide (valuvaigistite rühm, kuhu kuuluvad morfiin ja fentanüül).
English: For the full list of side effects with Instanyl, see the package leaflet.
Estonian: Instanyli kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Instanyl has been shown to provide rapid relief of pain in patients with cancer.
Estonian: Instanyl leevendab tõendatult kiiresti valu vähipatsientidel.
English: It must also not be used in patients who have had facial radiotherapy (treatment with radiation to the face) or who have recurrent episodes of epistaxis (nosebleeds).
Estonian: Samuti ei tohi seda kasutada patsiendid, kellele on tehtud näopiirkonna kiiritusravi või kellel on olnud korduvaid ninaverejookse.
English: It must not be used in patients treated with medicines containing sodium oxybate (used to treat narcolepsy, a sleep disorder).
Estonian: Seda ei tohi kasutada patsiendid, keda ravitakse ravimitega, mis sisaldavad naatriumoksübaati, mida kasutatakse narkolepsia (teatud unehäire) raviks.
English: In Instanyl, fentanyl is contained inside a nasal spray.
Estonian: Instanylis sisaldub fentanüül ninaspreis.
English: The first dose of Instanyl is 50 micrograms (one spray of the lowest strength) in one nostril; this is increased as necessary until reaching the dose that gives the patient adequate pain relief.
Estonian: Esimene Instanyli annus on 50 µg (väikseima tugevusega annuse üks pihustus) ühte ninasõõrmesse.
English: Why is Instanyl authorised in the EU?
Estonian: ELis Instanylile väljastatud müügiloa põhjendus
English: Annex IV Conditions for lifting the suspension
Estonian: IV LISA Peatamise lõpetamise tingimused
English: Evidence that the product has been reformulated, that it exhibits an acceptable release profile with the same quality, safety and efficacy profile of the currently authorised formulation but without the clinically significant interaction with alcohol.
Estonian: Andmed, et ravimi ravimvormi on muudetud, et ravimil on praegu kehtiva müügiloaga ravimiga sama kvaliteedi-, ohutus- ja efektiivsusprofiili korral toimeaine vastuvõetav vabastamisprofiil, kuid puudub kliiniliselt oluline koostoime alkoholiga.
English: The new formulation must be approved by the National Competent Authorities of the concerned Member States.
Estonian: Uue ravimvormi peab kinnitama asjaomase liikmesriigi riiklik pädev asutus.
English: Only applicable to products containing a polymethacrylate-triethylcitrate coating as modified-release mechanism
Estonian: Kehtib ainult ravimitele, mille toimeainet modifitseeritult vabastava mõju aluseks on polümetakrülaattrietüültsitraatkate.
English: Safety studies have shown that the strain is safe for turkeys.
Estonian: Ohutusuuringud on näidanud, et tüvi on kalkunitele ohutu.
English: However, precautionary measures must be followed in order to avoid direct or indirect contact between vaccinated chickens and turkeys.
Estonian: Siiski tuleb järgida ettevaatusabinõusid, et vältida otsest või kaudset kokkupuudet vaktsineeritud kanade ja kalkunite vahel.
English: The full EPAR for Innovax-ILT can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Innovax-ILT kohta on ameti veebilehel: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Innovax-ILT on 3 July 2015.
Estonian: Euroopa Komisjon andis Innovax-ILT müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 3. juulil
English: There are no known side effects.
Estonian: Vaktsiinil ei ole teadaolevaid kõrvalnähte.
English: This will help protect the chickens against ILT and MD.
Estonian: See aitab kaitsta kanu ILT ja MD eest.
English: Protection against ILT starts 4 weeks after vaccination and lasts 60 weeks.
Estonian: Kaitse ILT vastu tekib 4 nädalat pärast vaktsineerimist ja püsib 60 nädalat.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that InnovaxILT's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Veterinaarravimite komitee järeldas, et Innovax-ILT kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The disease is caused by a herpesvirus and can be mild (causing watery eyes, nasal discharge and mild inflammation of the windpipe) or severe, causing dyspnoea (difficulty breathing), respiratory depression and coughing up of blood.
Estonian: Haigust põhjustab herpesviirus ning see võib olla kerge (vesised silmad, eritis ninaavadest ja kerge hingetorupõletik) või raske, põhjustades düspnoed (hingamisraskusi), hingamisdepressiooni ja veriköha.
English: What is Innovax-ILT and what is it used for?
Estonian: Mis on Innovax-ILT ja milleks seda kasutatakse?
English: As the vaccine is stored in liquid nitrogen, it is important that any handling is done in a well-ventilated area and that precautions are taken when preparing the vaccine.
Estonian: Kuna vaktsiini säilitatakse vedelas lämmastikus, on tähtis, et käitlemine toimuks hästiventileeritavas kohas ja et vaktsiini ettevalmistamisel võetakse ettevaatusmeetmeid.
English: The turkey herpesvirus strain HVT/ILT-138 has been modified so that it will produce the glycoproteins gD and gI which form part of the outer coat of the ILT virus.
Estonian: Kalkuni herpesviiruse tüve HVT/ILT-138 on muudetud, et see toodaks glükoproteiine gD ja gI, mis on osa ILT viiruse väliskestast.
English: Birds infected with MD virus can be carriers and shedders of the virus for life.
Estonian: MD viirusega nakatunud linnud võivad olla viiruse kandjad ja edasiandjad kogu elu.
English: The withdrawal period for meat and eggs from chickens treated with Innovax-ILT is ‘zero' days, which means that there is no mandatory waiting time.
Estonian: Vaktsiiniga Innovax-ILT ravitud kanade liha ja munade keeluaeg on 0 päeva, mis tähendab, et keeluaega ei ole.
English: Other information about Innovax-ILT
Estonian: Muu teave Innovax-ILT kohta
English: This is a summary of the European public assessment report (EPAR) for Innovax-ILT.
Estonian: See on vaktsiini Innovax-ILT Euroopa avaliku hindamisaruande kokkuvõte.
English: Why is Innovax-ILT approved?
Estonian: Miks Innovax-ILT heaks kiideti?